Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
| ▸ | XIAP | P98170 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7532721 | 0.86 | AOC3 (0.32) | SMN1; SMN2AOC3 | |
| Trifluoroacetic Acid SCHEMBL7531136 | 0.83 | KDM4E (0.33) | HRH4HRH3SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL7541001 | 0.70 | MMP8 (0.34) | HRH4HRH3SMN1; SMN2AOC3KDM4E | |
| Trifluoroacetic Acid SCHEMBL7572001 | 0.70 | AOC3 (0.43) | HRH4HRH3AOC3KDM4EALDH1A1 | |
| SCHEMBL7531140 | 0.69 | — | — | |
| SCHEMBL3249168 | 0.67 | AOC3 (0.43) | SMN1; SMN2AOC3KDM4EALDH1A1GAA | |
| SCHEMBL12094891 | 0.67 | AOC3 (0.43) | SMN1; SMN2AOC3KDM4EALDH1A1GAA | |
| SCHEMBL3249047 | 0.67 | AOC3 (0.43) | SMN1; SMN2AOC3KDM4EALDH1A1GAA | |
| Trifluoroacetic Acid SCHEMBL7530146 | 0.67 | AOC3 (0.45) | HRH4HRH3AOC3ALDH1A1 | |
| SCHEMBL12094877 | 0.65 | AOC3 (0.42) | SMN1; SMN2AOC3KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198189-A1 | Treatment or prophylaxis of Semicarbazide-sensitive amine oxidase (SSAO) mediated complications in mammals including humans | BIOVITRUM AB (SE) | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198189-A1 | Treatment or prophylaxis of Semicarbazide-sensitive amine oxidase (SSAO) mediated complications in mammals including humans | AOC3, AOC2, AOC1 | HRH4 148/4885HRH3 77/4885SMN1; SMN2 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.